Ultima UG200 Chosen for 80,000-Sample UK Biobank Immune Study

Ultima Genomics' UG200 Sequencing Platform was selected for an 80,000-sample immune profiling study with IMU Biosciences and UK Biobank, aiming to create a detailed immune dataset for AI research. The study integrates IMU's HD Immunology platform, Waters Corporation's multiomics tools, and Ultima's sequencing to analyze immune variation related to disease and health outcomes.